Argos to begin Phase III of renal carcinoma drug in combination with sunitinib
07 February 2012
Pial Ganguli
Please Login to read the full article.
07 February 2012
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- Argos shoots for $86M IPO for PhIII metastatic RCC immunotherapy candidate
- 4SC steps up partnering efforts as key resminostat data comes in ahead of schedule
- US FDA accepts Pfizer's axitinib filing in renal cell carcinoma
- NICE plans appraisal for Pfizer's Inlyta in RCC where others have failed
ANALYSIS
Other Informa Analysis
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
